

3-(4-Fluorobenzyl)-2-thioxo-3,4,5,6-tetrahydropyrimidin-4(1H)-one

Chang-Sheng Yao, Hai-Bin Song,
You-Quan Zhu, Ying Gao,
Fang-Zhong Hu, Xiao-Mao Zou
and Hua-Zheng Yang*State Key Laboratory and Institute of Elemento-
Organic Chemistry, Nankai University, Weijin
Road No 94, Tianjin, People's Republic of
ChinaCorrespondence e-mail:
chshengyao@mail.nankai.edu.cn

Key indicators

Single-crystal X-ray study
 $T = 293\text{ K}$
Mean $\sigma(\text{C}-\text{C}) = 0.03\text{ \AA}$
 R factor = 0.032
 wR factor = 0.096
Data-to-parameter ratio = 13.8For details of how these key indicators were
automatically derived from the article, see
<http://journals.iucr.org/e>.The tetrahydropyrimidine ring of the title molecule, $\text{C}_{11}\text{H}_{11}\text{FN}_2\text{OS}$, adopts a half-chair conformation. In the crystal structure, the molecules are linked to form centrosymmetric hydrogen-bonded dimers.Received 20 September 2004
Accepted 24 September 2004
Online 30 September 2004

Comment



Derivatives of uracil and thiouracil are of interest because of their wide-ranging bioactivity (Gupta *et al.*, 2004; South *et al.*, 2003). For example, lenacil, bromacil, butafenacil, fluproacil, isocil and terbacilare are widely used as herbicides. Some derivatives also exhibit antidiabetic activity (Soliman, 1979). In addition, compounds that contain fluorine have special bioactivity; for example, flumioxazin is a widely used herbicide (Hermann *et al.*, 2003; Ulrich, 2004). This led us to study the synthesis and relationship between structure and herbicidal activity in a variety of fluorinated derivatives of uracil and thiouracil. We report here the crystal structure of the title compound, (I).

Figure 1
The structure of (I), showing 40% probability displacement ellipsoids and the atom-numbering scheme. H atoms are drawn as spheres of arbitrary radius.

The molecular structure of (I) is shown in Fig. 1. The tetrahydropyrimidine ring adopts a half-chair conformation, similar to that observed in related structures (Lorente & Aurrecoechea, 1994; Rohrer & Sundaralingam, 1968; Furberg & Jensen, 1968; Yao *et al.*, 2004*a,b*). The conformation of the attachment of the benzene ring to the tetrahydropyrimidine ring is described by the torsion angle C1–N2–C5–C6 of 103.52 (17)°. In the crystal structure, centrosymmetrically related molecules form dimeric pairs through intermolecular N–H···S hydrogen bonds (Fig. 2 and Table 1).

Experimental

According to the reported procedure of Hatam *et al.* (1996), the title compound was synthesized by refluxing methyl 3-(((4-fluorobenzyl)amino)carbonothioyl)amino)propanoate in triethylamine for about 2 h. After cooling, the precipitate was filtered off and recrystallized from a mixture of acetone and ethanol, giving single crystals suitable for X-ray diffraction.

Crystal data

$C_{11}H_{11}FN_2OS$	$Z = 2$
$M_r = 238.28$	$D_x = 1.385 \text{ Mg m}^{-3}$
Triclinic, $P\bar{1}$	Mo $K\alpha$ radiation
$a = 6.392 (3) \text{ \AA}$	Cell parameters from 1012 reflections
$b = 9.081 (4) \text{ \AA}$	$\theta = 3.3\text{--}26.5^\circ$
$c = 11.099 (5) \text{ \AA}$	$\mu = 0.28 \text{ mm}^{-1}$
$\alpha = 113.793 (6)^\circ$	$T = 293 (2) \text{ K}$
$\beta = 95.328 (7)^\circ$	Prism, colorless
$\gamma = 99.931 (6)^\circ$	$0.22 \times 0.20 \times 0.18 \text{ mm}$
$V = 571.2 (4) \text{ \AA}^3$	

Data collection

Bruker SMART CCD area-detector diffractometer	2005 independent reflections
φ and ω scans	1725 reflections with $I > 2\sigma(I)$
Absorption correction: multi-scan (SADABS; Sheldrick, 1996)	$R_{\text{int}} = 0.014$
$T_{\text{min}} = 0.772$, $T_{\text{max}} = 1.000$	$\theta_{\text{max}} = 25.0^\circ$
2984 measured reflections	$h = -7 \rightarrow 6$
	$k = -10 \rightarrow 8$
	$l = -8 \rightarrow 13$

Refinement

Refinement on F^2	$w = 1/[\sigma^2(F_o^2) + (0.0482P)^2 + 0.1179P]$
$R[F^2 > 2\sigma(F^2)] = 0.032$	where $P = (F_o^2 + 2F_c^2)/3$
$wR(F^2) = 0.096$	$(\Delta/\sigma)_{\text{max}} = 0.005$
$S = 1.07$	$\Delta\rho_{\text{max}} = 0.20 \text{ e \AA}^{-3}$
2005 reflections	$\Delta\rho_{\text{min}} = -0.16 \text{ e \AA}^{-3}$
145 parameters	
H-atom parameters constrained	

Table 1

Hydrogen-bonding geometry (Å, °).

$D\text{--}H\cdots A$	$D\text{--}H$	$H\cdots A$	$D\cdots A$	$D\text{--}H\cdots A$
$N1\text{--}H1A\cdots S1^i$	0.90	2.71	3.4905 (18)	146
$N1\text{--}H1A\cdots O1^{ii}$	0.90	2.59	3.035 (2)	111

Symmetry codes: (i) $1 - x, 1 - y, 1 - z$; (ii) $1 + x, y, z$.

H atoms were placed in calculated positions, with C–H = 0.93 or 0.97 Å and N–H = 0.90 Å, and included in the final cycles of




Figure 2

N–H···S hydrogen-bonded dimers in (I), viewed down the *c* axis. Intermolecular hydrogen bonds are indicated by dashed lines.

refinement using a riding model, with $U_{\text{iso}}(\text{H}) = 1.2U_{\text{eq}}(\text{parent atom})$.

Data collection: SMART (Bruker, 1998); cell refinement: SAINT (Bruker, 1999); data reduction: SAINT; program(s) used to solve structure: SHELXS97 (Sheldrick, 1997); program(s) used to refine structure: SHELXL97 (Sheldrick, 1997); molecular graphics: SHELXTL (Bruker, 1999); software used to prepare material for publication: SHELXTL.

The authors acknowledge the financial support of the National Natural Science Foundation of China (grant No. 20372040) and the Doctor's Special Foundation of the High Education Ministry (grant No. 20020055022).

References

- Bruker (1998). SMART. Bruker AXS Inc., Madison, Wisconsin, USA.
 Bruker (1999). SAINT and SHELXTL. Bruker AXS Inc., Madison, Wisconsin, USA.
 Furberg, S. & Jensen, L. H. (1968). *J. Am. Chem. Soc.* **90**, 470–474.
 Gupta, S., Pulman, D. A. & Roh, T. (2004). US Patent No. 20 040 018 941.
 Hatam, M., Kopper, S. & Martens, J. (1996). *Heterocycles*, **43**, 1653–1663.
 Hermann, B., Erwin, H., Hansjorg, K. (2003). US Patent No. 2 003 176 284.
 Lorente, A. & Aurrecoechea, L. M. (1994). *Heterocycles*, **38**, 1077–1087.
 Rohrer, D. & Sundaralingam, M. (1968). *J. Chem. Soc. Chem. Commun.* pp. 746–747.
 Sheldrick, G. M. (1996). SADABS. University of Göttingen, Germany.
 Sheldrick, G. M. (1997). SHELXS97 and SHELXL97. University of Göttingen, Germany.
 Soliman, R. (1979). *J. Med. Chem.* **22**, 351–353.
 South, M. S., Jones, D. E. & Rueppel, M. L. (2003). US Patent No 20 030 023 086.
 Ulrich, H. (2004). US Patent No. 2 004 033 897.
 Yao, C.-S., Song, H.-B., Zhu, Y.-Q., Gao, Y., Hu, F.-Z., Zou, X.-M. & Yang, H.-Z. (2004a). *Acta Cryst.* **E60**, o943–o945.
 Yao, C.-S., Song, H.-B., Zhu, Y.-Q., Gao, Y., Hu, F.-Z., Zou, X.-M. & Yang, H.-Z. (2004b). *Acta Cryst.* **E60**, o1411–o1413.